Diabetes and Metabolic Disorders: The Approval of Teplizumab
Teplizumab, the first disease-modifying therapy for Type 1 diabetes, delays disease onset by ~4 years in high-risk individuals. Priced at $194,000 per course, it redefines early intervention despite cost barriers.
June 23, 2025
by David Orchard-Webb
Sterilization Processes in the Pharmaceutical Industry
In this post, we'll look at the numerous sterilization techniques utilized in the pharmaceutical sector, as well as their uses and benefits in terms of product safety and regulatory compliance.
May 6, 2025
by David Orchard-Webb